Variable therapeutic response in asthma: A genetic perspective

Personalized Medicine

Volumn 3, Issue 1, 2006, Pages 61-78

  Bhatnagar, Pallav ^a   Guleria, Randeep ^b   Kukreti, Ritushree ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Asthma; Drug response; Pharmacogenetics; Pharmacogenomics; Single nucleotide polymorphisms

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ANTIASTHMATIC AGENT; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ATRELEUTON; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FENOTEROL; FORMOTEROL; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUTAMINE; GLYCINE; LEUKOTRIENE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MONTELUKAST; MUSCARINIC M3 RECEPTOR; PLACEBO; PRANLUKAST; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; TERBUTALINE; THEOPHYLLINE DERIVATIVE; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ASTHMA; BRONCHODILATING ACTIVITY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MOLECULAR GENETICS; NONHUMAN; PEAK EXPIRATORY FLOW; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION;

EID: 33646775718     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.3.1.61     Document Type: Review

References (101)

1. Global Initiative for Asthma: Global strategy for asthma management and prevention, Bethesda, MD: National Institute of Health; Publication No. 02-3659 (2002).
2. National Asthma Education and Prevention Program: Expert panel report 2: Guidelines for the diagnosis and management for asthma. Bethesda, MD: National Institute of Health; Publication No. 55-4051 (1997).
3. Worldwide variations in the prevalence of asthma symptoms: the international study of asthma and allergies In childhood (ISAAC). Eur. Repir. J. 12(2), 315-335 (1998).
4. Mannino DM, Iloma DM, Pertowski CA et al.: Surveillance for asthma: United States, 1960-1995. Morb Mortal Wkly Rep 47, 1-27 (1998).
5. Masoli M, Fabian D, Holt S, Beasley R: The global burden of asthma: Executive summary of the GINA Dissemination Committee Report. Allergy 59(5), 469-478 (2004).
6. Guidelines for management of asthma at primary and secondary levels of health care in India: WHO - Govt. of India Collaborative Programme, 1-43 (2005).
7. Hall IP: Pharmacogenetics of asthma. Eur: Respir. J. 15, 449-451 (2000).
8. Palmer LJ, Cookson WO: Genomic approaches to understanding asthma. Genome Res. 10, 1280-1287 (2000)
9. Weiss ST: Gene by environment interaction and asthma. Clin. Exp. Allergy 29 (Suppl 2), 96-99 (1999).
10. Annesi-Maesano I: Asthma epidemiology. Rev Prat. 55(12), 1295-1298 (2005)
11. Keller MB, Lowenstein SR: Epidemiology of asthma. Semin Respir Crit. Care Med. 23(4), 317-329 (2002).
12. Dewar JC, Hall IP: Personalised prescribing for asthma - is pharmacogenetics the answer? J. Pharm. Pharmacol. 55(3), 279-289 (2003).
13. Johnson JA: Drug target pharmacogenomics: an overview. Am. J. Pharmacogenomics 1(4), 271-281 (2001).
14. Pastinen T, Sladek R, Gurd S et al.: A survey of genetic and epigenetic variation affecting human gene expression. Physiol. Genomics 16(2), 184-193 (2004).
15. 2 receptor agonists in asthma: a comparison. J. Asthma 27(2), 101-109 (1990).
16. 2-adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 43(9), 674-678 (1988).
17. Silverman R: Treatment of acute asthma: a new look at the old and at the new. Clin. Chest Med. 21, 361-379 (2000).
18. Small KM, McGraw DW, Liggett SB: Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu. Rev. Pharmacol. Toxicol. 43, 381-411 (2003).
19. 2-adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Cell Mol. Biol. 8(3), 334-339 (1993).
20. 2-adrenergic receptor and asthma. Am. J. Respir. Crit. Care Med. 156, S156-S162 (1997).
21. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33(32), 9414-9419 (1994).
22. 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 13, 25-33 (1995).
23. 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. 100(12). 3184-3188 (1997).
24. 2-adrenergic receptor polymorphisms affect airway responsiveness to salbutamol in asthmatics. J. Asthma 36, 583-590 (1999).
25. 2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin. Pharmacol. Ther. 65(5), 519-525 (1999).
26. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am. J. Respir. Crit. Care Med. 162(1), 75-80 (2000).
27. 2-adrenergic receptor polymorphisms in the childhood asthma management program. J. Allergy Clin. Immunol. 112(5), 870-876 (2003).
28. Choudhry S, Ung N, Avila PC et al.: Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am. J. Respir. Crit. Care Med. 171(6), 563-570 (2005).
29. 2-adrenergic receptor polymorphisms and response to salbutamol among Indian asthmatics. Pharmacogenomics. 6(4), 399-410 (2005).
30. 2-agonist therapy in asthma. Eur. Respir. J. 11(3), 589-593 (1998).
31. Israel E, Chinchilli VM, Ford JG et al.: Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled cross-over trial. Lancet (364), 1505-1512 (2004).
32. 2-adrenoceptor polymorphisms: are they clinically important? Thorax 51 (4), 351-353 (1996).
33. 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 345, 1213-1214 (1995).
34. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J. Biol. Chem. 268(31), 23116-23121 (1993).
35. 2 adrenergic receptor mRNA inhibits receptor synthesis. J. Biol. Chem. 269(6), 4497-4505 (1994).
36. Bader JS: The relative power of SNPs and haplotype as genetic markers for association tests. Pharmacogenomics 2(1), 11-24 (2001).
37. Drysdale CM, McGraw DW, Stack CB et al.: Complex promoter and coding region β-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl Acad. Sci. USA 97(19), 10483-10488 (2000).
38. British Thoracic Society. The British guidelines on asthma management: review and position statement. Thorax 52 (Suppl. 1), 1-21 (1997).
39. Beato M: Gene regulation by steroid hormones. Cell 56, 335-344 (1989).
40. 2-adrenergic receptor transcription in human lung. Am. J. Physiol. 12, L41-L46 (1995).
41. Koper JW, Stolk RP, de Lange P et al.: Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum. Genet. 99(5), 663-668 (1997).
42. Ruiz M, Lind U, Gafvels M et al.: Characterization of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance. Clin. Endocrinol. 55(3), 363-371 (2001).
43. Hurley DM, Accili D, Stratakis CA et al.: Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J. Clin. Invest. 87(2), 680-686 (1991).
44. Malchoff DM, Brufsky A, Reardon G et al.: A mutation of the glucocorticoid receptor in primary cortisol resistance. J. Clin. Invest. 91(5), 1918-1925 (1993).
45. Huizenga NA, Koper JW, De Lange P et al.: A polymorphism in the glucocorticoid receptor gene may be associated with an increased sensitivity to glucocorticoids in vivo. J Clin. Endocrinol. Metab. 83(1), 144-151 (1998).
46. Pfahl M: Nuclear receptor/AP-1 interactions. Endocrinol Rev. 14(5), 651-658 (1993).
47. Ray A, Prefontaine KE: Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Proc. Natl Acad. Sci. USA 91(2), 752-756 (1994).
48. Barnes PJ, Adcock IM: Transcription factors and asthma. Eur. Respir. J. 12(1), 221-234 (1998).
49. Adcock IM: Steroid resistance in asthma: molecular mechanisms. Am. J. Respir. Crit. Care Med. 154, S58-S61 (1996).
50. Lane SJ, Adcock IM, Richards D, Hawrylowicz C, Barnes PJ, Lee TH: Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes. J. Clin. Invest. 102(12), 2156-2164 (1998).
51. Umino Y, Hohjoh H, Tokunaga K: Novel single nucleotide polymorphisms (SNPs) at positions 497 (T/G) and 829 (T/C) in the human c-FOS gene and haplotype association. Hum. Mutat. 16(3), 279 (2000).
52. Weiss ST, Lake SL, Silverman ES et al.: Asthma steroid pharmacogenetics: a study strategy to identify replicated treatment responses. Proc. Am. Thorac. Soc. 1(4), 364-367 (2004).
53. Tantisira KG, Lake S, Silverman ES et al.: Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum. Mol. Genet. 13(13), 1353-1359 (2004).
54. The Childhood Asthma Management Program Group. The Childhood Asthma Management Program (CAMP): design, rationale, and methods. Control. Clin. Trials 20, 91-120 (1999).
55. Tantisira KG, Hwang ES, Raby BA et al.: TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc. Natl Acad. Sci. USA 101(52), 18099-18104 (2004).
56. Barnes N: New drugs for asthma. Practitioner 237, 870-873 (1993).
57. Barnes NC, Kuitert LM: Drugs affecting the leukotriene pathway in asthma. Br. J. Clin. Pract. 49, 262-266 (1995).
58. Barnes N: Leukotriene receptor antagonists: clinical effects. J. R. Soc. Med. 90, 200-204 (1997).
59. Samuelsson B: Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220(4597), 568-575 (1983).
60. Griffin M, Weiss JW, Leitch AG et al.: Effects of leukotriene D on the airways in asthma. N. Engl. J. Med. 308(8), 436-439 (1983).
61. Davidson AB, Lee TH, Scanlon PD et al.: Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects. Am. Rev. Respir. Dis. 135(2), 333-337 (1987).
62. Drazen JM: Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma. Pharmacotherapy 17(1 Pt 2), 22S-30S (1997).
63. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN: Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237 (4819), 1171-1176 (1987).
64. In KH, Asano K, Beier D et al.: Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J. Clin. Invest. 99(5), 1130-1137 (1997).
65. Silverman ES, Du J, De Sanctis GT et al.: Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants. Am. J. Respir. Cell Mol. Biol. 19(2), 316-323 (1998).
66. Drazen JM, Yandava CN, Dube L et al.: Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet. 22(2), 168-170 (1999).
67. Anderson W, Kalberg C, Edward L et al.: Effects of polymorphisms in the promoter region of 5-lipoxygenase and LTC4 synthase on the clinical response to zafirlukast and fluticasone. Eur. Respir. J. 16(Suppl B), 183s (2000).
68. Lynch KR, O'Neill GP, Liu Q et al.: Characterization of the human cysteinyl leukotriene CysLTI receptor. Nature 399(6738), 789-793 (1999).
69. Sampson AP, Siddiqui S, Buchanan D et al.: Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 55(Suppl. 2), S28-S31 (2000).
70. 4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 350 (9091), 1599-1600 (1997).
71. Page CP: Recent advances in our understanding of the use of theophylline in the treatment of asthma. J. Clin. Pharmacol. 39(3), 237-240 (1999).
72. Ginchansky E, Weinberger M: Relationship of theophylline clearance to oral dosage in children with chronic asthma. J. Pediatr. 91(4), 655-660 (1977).
73. Ellis EF, Koysooko R, Levy G: Pharmacokinetics of theophylline in children with asthma. Pediatrics 58(4), 542-547(1976).
74. Miller CA, Slusher LB, Vesell ES: Polymorphism of theophylline metabolism in man. J. Clin. Invest. 75(5), 1415-1425 (1985).
75. Gross NJ: Ipratropium bromide. N. Engl. J. Med. 319, 486-494 (1988).
76. Mak JC, Baraniuk JN, Barnes PJ: Localization of muscarinic receptor subtype mRNAs in human lung. Am. J. Respir. Cell Mol. Biol. 7(3), 344-348 (1992).
77. Roffel AF, Elzinga CRS, Zaagsma J: Muscarinic M3 receptor mediates contraction of human central and peripheral airway smooth muscle. Pulmon. Pharmacol. 3, 47-51 (1990).
78. Yang CM, Chou SP, Sung TC: Muscarinic receptor subtypes coupled to generation of different second messengers in isolated tracheal smooth muscle cells. Br. J. Pharmacol. 104(3), 613-618 (1991).
79. Fernandes LB, Fryer AD, Hirshman CA: M2 muscarinic receptors inhibit isoproterenol-induced relaxation of canine airway smooth muscle. J. Pharmacol. Exp. Ther. 262(1), 119-126 (1992).
80. Fenech AG, Ebejer MJ, Felice AE, Ellul-Micallef R, Hall IP: Mutation screening of the muscarinic M(2) and M(3) receptor genes in normal and asthmatic subjects. Br. J. Pharmacol. 133(1), 43-48 (2001).
81. Yamamoto T, Yamashita N, Kuwabara M et al.: Mutation screening of the muscarinic M2 and M3 receptor genes in asthmatics, outgrow subjects, and normal controls. Ann. Genet. 45(3), 109-113 (2002).
82. Fenech AG, Billington CK, Swan C et al.: Novel polymorphisms influencing transcription of the human CHRM2 gene in airway smooth muscle. Am. J. Respir. Cell Mol. Biol. 30(5), 678-686 (2004).
83. Daly AK, Fairbrother KS, Smart J: Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. Toxicol. Lett. 102-103, 143-147 (1998).
84. Ingelman-Sundberg M, Oscarson M, McLellan RA: Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci. 20(8), 342-349 (1999).
85. 4 receptor antagonist, in humans. Drug Metab. Dispos. 25(9), 1022-1031 (1997).
86. Manchee GR, Eddershaw PJ, Ranshaw LE et al.: The aliphatic oxidation of salmeterol to α-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A. Drug Metab. Dispos. 24(5), 555-559 (1996).
87. Jonsson G, Astrom A, Andersson P: Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab. Dispos. 23(1), 137-142 (1995).
88. Zhang ZY, Kaminsky LS: Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem. Pharmacol. 50(2), 205-211 (1995).
89. Ieiri I, Tainaka H, Morita T et al.: Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in the human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther. Drug Monit. 22(3), 237-244 (2000).
90. Ou-Yang DS, Huang SL, Wang W et al.: Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br. J. Clin. Pharmacol. 49(2), 145-151 (2000).
91. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T: Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol. Biomarkers Prev. 3(5), 413-421 (1994).
92. Chida M, Yokoi T, Fukui T, Kinoshita M, Yokota J, Kamataki T: Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J. Cancer Res. 90(9), 899-902 (1999).
93. Welfare MR, Aitkin M, Bassendine MF, Daly AK: Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians. Pharmacogenetics 9(3), 367-375 (1999).
94. Sachse C, Brockmoller J, Bauer S, Roots I: Functional significance of a C → A polymorphism in intron 1 of the Cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 47(4), 445-449 (1999).
95. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T: Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem. (Tokyo) 125(4), 803-808 (1999).
96. Macciardi F: Statistical Approaches in Psychopharmacogenetics. In: Pharmacogenetics of Psychotropic Drugs. Lerer B (Ed.), Cambridge University Press, Cambridge, UK, 72-91 (2002).
97. Cardon LR, Palmer LJ: Population stratification and spurious allelic association. Lancet 361(9357), 598-604 (2003).
98. 2-adrenergic receptor signaling pathways. J. Allergy Clin. Immunol. 110(6 Suppl), S229-S235 (2002).
99. 2 adrenoceptor polymorphism and susceptibility to bronchodilator desensitization in moderately severe stable asthmatics. Lancet 350(9083), 995-999 (1997).
100. 2-agonist therapy. Clin. Sci. (Lond) 96(3), 253-259 (1999).
101. 2-adrenergic receptor on response to regular use of albuterol in asthma. Int. Arch. Allergy Immunol. 124(1-3), 183-186 (2001).